Medications

Aflibercept in AMD: No proof of added benefit

It is not proven that patients with wet age-related macular degeneration benefit from the new drug aflibercept, as the drug manufacturer did not present any suitable data for a comparison with the current standard therapy ...

Medications

Lanadelumab in hereditary angioedema: Added benefit not proven

The monoclonal antibody lanadelumab has been approved in Europe since 2015 as a long-term prophylaxis to prevent attacks of hereditary angioedema. Since this is a rare disease, the Federal Joint Committee (G-BA) initially ...

Diseases, Conditions, Syndromes

Massachusetts: Fungus at meningitis-linked firm

(AP)—Massachusetts state officials investigating a pharmacy linked to a deadly outbreak of meningitis said Tuesday they found shoddy sterilization practices and unclean conditions there, including debris-covered floor mats ...

Other

China launches crackdown on drug industry

(AP)—China announced a crackdown Wednesday on misconduct in its drug market, stepping up pressure on the problem-prone industry while it pursues a bribery investigation of GlaxoSmithKline.

page 14 from 21